Drug intelligence / Profile preview

gemcitabine + oxaliplatin + lenvatinib + toripalimab + hepatic arterial infusion chemotherapy

Development stage: Unknown
Lead developer: Sun Yat-sen University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Hepatic Arterial Infusion

Overview

This combination therapy is an investigational regimen developed by Sun Yat-sen University for the treatment of advanced or unresectable intrahepatic cholangiocarcinoma (ICC). The regimen integrates systemic chemotherapy (GemOx: gemcitabine and oxaliplatin), the multikinase inhibitor lenvatinib, and the anti-PD-1 monoclonal antibody toripalimab, supplemented by Hepatic Arterial Infusion Chemotherapy (HAIC) using oxaliplatin. This multimodal approach aims to leverage the cytotoxic effects of chemotherapy, the anti-angiogenic and anti-proliferative properties of lenvatinib, and the immune-restoring capabilities of toripalimab. The addition of HAIC provides a localized, high-concentration delivery of chemotherapy directly to the liver via the hepatic artery, potentially improving local tumor control and overall survival in patients with advanced ICC.

Other names: HAIC + GemOx + Lenvatinib + ToripalimabHAIC-GemOx-Lenvatinib-Toripalimab

Targets

FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on gemcitabine + oxaliplatin + lenvatinib + toripalimab + hepatic arterial infusion chemotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + oxaliplatin + lenvatinib + toripalimab + hepatic arterial infusion chemotherapy.

Explore the full profile